GLPwatch
Papers (9189)
Page 143 of 154, ranked by citation count.
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
- Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry.
- Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
- Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism.
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications.
- Diagnostic Performance of Exendin-4 PET/CT in Localizing Insulinomas: A Systematic Review and Meta-analysis.
- Oppositely biased glucagon-like peptide-1 receptor agonism does not differentially affect lipid metabolism in APOE*3-Leiden CETP mice.
- Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.
- [Conserved W52 led to reduced binding of glucogan-like peptide 1 receptor].
- Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
- Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
- The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.
- Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.
- Exenatide dosing in alpacas.
- Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis.
- GLP-1 and the cardiovascular system.
- Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.
- Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.
- Lax oversight of semaglutide advertising could harm patients, warn critics.
- Semaglutide and Cardiovascular Outcomes.
- [Cloning, expressing of exendin-4 analogue and bioactivity analysis in vivo].
- Use of semaglutide and tirzepatide among people with multiple sclerosis.
- [The effect of exenatide analogs on hydruretic function of rat kidney under water load].
- Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier.
- Illeum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
- Short-Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy.
- [Effect of semaglutide on serum metabolomics in obese patients with type 2 diabetes mellitus complicated with metabolic-associated fatty liver disease].
- Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
- [Effects of exendin-4 on extracellular matrix metabolism in human mesangial cells cultured in high glucose].
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Antidiabetikum vor neuer Karriere.
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.
- Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
- Weight regain after bariatric surgery: A framework for management.
- [Technological Innovations in Diabetes Therapy].
- [Among adults with cardiovascular disease and BMI≥27kg/m<sup>2</sup> but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]
- The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
- Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.
- Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
- Bile acid diarrhoea.
- Developing <sup>68</sup>Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
- Ozempic and dental therapy.
- [Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury].
- Intense Uptake of 68 Ga-exendin-4 in a Patient With WHO Grade 3 Insulinoma and Extensive Intrahepatic Metastases.
- [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]
- Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide: A Preformulation Study.
- [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
- Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity.
- Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived β cells during transplantation.
- The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial.
- Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
- Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.
- [Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].
- Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
- <sup>68</sup>Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond.